Free Trial

Kenvue (KVUE) Stock Forecast & Price Target

Kenvue logo
$23.78 +0.09 (+0.38%)
(As of 11/20/2024 ET)

Kenvue - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
1
Hold
7
Buy
4

Based on 12 Wall Street analysts who have issued ratings for Kenvue in the last 12 months, the stock has a consensus rating of "Hold." Out of the 12 analysts, 1 has given a sell rating, 7 have given a hold rating, and 4 have given a buy rating for KVUE.

Consensus Price Target

$22.64
-4.81% Downside
According to the 12 analysts' twelve-month price targets for Kenvue, the average price target is $22.64. The highest price target for KVUE is $27.00, while the lowest price target for KVUE is $18.00. The average price target represents a forecasted downside of -4.81% from the current price of $23.78.
Get the Latest News and Ratings for KVUE and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Kenvue and its competitors.

Sign Up

KVUE Analyst Ratings Over Time

TypeCurrent Forecast
11/22/23 to 11/21/24
1 Month Ago
10/23/23 to 10/22/24
3 Months Ago
8/24/23 to 8/23/24
1 Year Ago
11/22/22 to 11/22/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
4 Buy rating(s)
4 Buy rating(s)
5 Buy rating(s)
8 Buy rating(s)
Hold
7 Hold rating(s)
7 Hold rating(s)
7 Hold rating(s)
6 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$22.64$22.64$22.64$26.92
Forecasted Upside-4.81% Downside-1.28% Downside3.77% Upside34.31% Upside
Consensus Rating
Hold
Hold
Hold
Moderate Buy

KVUE Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

KVUE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Kenvue Stock vs. The Competition

TypeKenvueConsumer Staples CompaniesS&P 500
Consensus Rating Score
2.25
2.47
2.50
Consensus RatingHoldHoldModerate Buy
Predicted Upside-4.81% Downside40.75% Upside9.83% Upside
News Sentiment Rating
Very Positive News

See Recent KVUE News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
10/22/2024Bank of America
4 of 5 stars
 Boost TargetBuy ➝ Buy$24.00 ➝ $27.00+18.11%
10/11/2024JPMorgan Chase & Co.
3 of 5 stars
 Boost TargetOverweight ➝ Overweight$24.00 ➝ $25.00+17.15%
9/24/2024Jefferies Financial Group
2 of 5 stars
 Initiated CoverageBuy$27.00+17.29%
9/24/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
N. Modi
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Sector Perform$24.00+4.26%
9/23/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$20.00 ➝ $21.00-8.77%
8/7/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$23.00 ➝ $24.00+14.72%
8/7/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$20.00 ➝ $22.00+5.36%
7/10/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$21.00 ➝ $20.00+13.06%
5/8/2024HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetHold ➝ Hold$20.00 ➝ $21.00+3.09%
4/11/2024Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageUnderperform$18.00-11.02%
4/3/2024William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Andersen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageMarket Perform
3/1/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy ➝ Neutral$20.00+5.24%
9/7/2023Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$28.00+25.06%
9/6/2023Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageHold
7/25/2023Edward Jones
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy
5/30/2023BNP Paribas
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageNeutral$28.00+6.46%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 09:14 AM ET.


Should I Buy Kenvue Stock? KVUE Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, November 4, 2024. Please send any questions or comments about these Kenvue pros and cons to contact@marketbeat.com.

Kenvue
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Kenvue Inc.:

  • Kenvue Inc. has recently increased its dividend from $0.20 to $0.205 per share, indicating a positive outlook on the company's financial health and commitment to rewarding shareholders.
  • Analysts have given Kenvue Inc. an average rating of "Hold" with a price target of $22.10, suggesting a potential for growth and stability in the stock price.
  • Kenvue Inc. reported earnings per share of $0.32 for the quarter, surpassing the consensus estimate of $0.28 by $0.04, showcasing strong financial performance.
  • The company has a market capitalization of $44.29 billion, indicating a significant presence in the market and potential for long-term growth.
  • Kenvue Inc. operates in the consumer health sector worldwide, a resilient industry with steady demand and growth opportunities.

Kenvue
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Kenvue Inc. for these reasons:

  • Despite positive aspects, Kenvue Inc. has received mixed ratings from analysts, with one sell rating and a majority of hold ratings, indicating uncertainty in the stock's performance.
  • The stock's current price of $23.02 on the NYSE may be considered high by some investors, potentially limiting short-term gains.
  • With a dividend payout ratio of 105.13%, Kenvue Inc. is distributing more in dividends than its earnings, which could raise concerns about sustainability and future growth.
  • Recent downgrades by analysts, such as the shift from an "outperform" to a "sector perform" rating, may signal potential challenges or headwinds for the company.
  • While the company has shown resilience, the consumer health sector can be competitive and subject to regulatory changes, posing risks to Kenvue Inc.'s operations and profitability.

KVUE Forecast - Frequently Asked Questions

According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for Kenvue is $22.64, with a high forecast of $27.00 and a low forecast of $18.00.

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kenvue in the last twelve months. There is currently 1 sell rating, 7 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" KVUE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KVUE, but not buy additional shares or sell existing shares.

According to analysts, Kenvue's stock has a predicted downside of -4.81% based on their 12-month stock forecasts.

Over the previous 90 days, Kenvue's stock had 1 downgrade by analysts.

Kenvue has been rated by research analysts at Bank of America, Jefferies Financial Group, JPMorgan Chase & Co., Piper Sandler, and Royal Bank of Canada in the past 90 days.

Analysts like Kenvue less than other "consumer staples" companies. The consensus rating score for Kenvue is 2.25 while the average consensus rating score for "consumer staples" companies is 2.47. Learn more on how KVUE compares to other companies.


This page (NYSE:KVUE) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners